This fits an earlier report by Frank et al. who described the association of PON2 with Imatinib resistance in CML patients in a BCR-ABL (Philadelphia chromosome)-independent manner [29]. The gene discussed is PON2; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.